EntryPoint Capital’s Niagen Bioscience NAGE Stock Holding History

EntryPoint Capital’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-38,077	Closed	-$263K	–	863
2025 Q1	$263K	Buy	38,077 +9,014	+31%	+$56.6K	0.12%	400
2024 Q4	$154K	Buy	+29,063	New	+$159K	0.06%	629

Other funds holding NAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

EntryPoint Capital's NAGE Position: Q2 2025 in Review

EntryPoint Capital sold out of Niagen Bioscience (NAGE) in Q2 2025, closing a stake of 38,077 shares — an estimated $263K sold.

EntryPoint Capital first reported a position in NAGE in Q4 2024 and held it in 2 quarters. The position peaked at $263K in Q1 2025. 155 funds tracked by Wall St. Rank hold NAGE as of Q2 2025.

EntryPoint Capital reported no remaining Niagen Bioscience position as of Q2 2025 after selling out during the quarter.
EntryPoint Capital sold 38,077 Niagen Bioscience shares in Q2 2025, an estimated $263K.
EntryPoint Capital first reported a position in Niagen Bioscience in Q4 2024 and held it in 2 quarters.
EntryPoint Capital's Niagen Bioscience position peaked at $263K in Q1 2025.
155 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2025.

Based on EntryPoint Capital's 13F filing for Q2 2025, filed 11 Aug 2025.